IFNB1 and myeloid sarcoma: At the time of the last documented visit, pharmacological treatment of MS consisted of fingolimod (15.3%, 9/59), interferon-beta (13.6%, 8/59), glatiramer acetat (6.8%, 4/59), dimethylfumarat (3.4%, 2/59), mitoxantron (1.7%, 1/59) or natalizumab (1.7%, 1/59).